Dupilumab as a potential steroid-sparing treatment for IgG4-related disease
Open Access
- 12 January 2020
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 81 (2), e24
- https://doi.org/10.1136/annrheumdis-2020-216945
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Dupilumab as a novel steroid-sparing treatment for IgG4-related diseaseAnnals Of The Rheumatic Diseases, 2020
- IgG4‐related disease: review of the histopathologic features, differential diagnosis, and therapeutic approachAPMIS, 2018
- Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patientsPLOS ONE, 2017
- Rituximab hypersensitivity in IgG4-related disease: successful desensitization in a patient with IgG4 rheumatoid factorInternational Journal of Rheumatic Diseases, 2016
- Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysisAnnals Of The Rheumatic Diseases, 2016
- International Consensus Guidance Statement on the Management and Treatment of IgG4‐Related DiseaseArthritis & Rheumatology, 2015